30S.F SANIONA AB (PUBL)
- Market cap
- EUR 145M
- P/E
- 8.8x
- P/B
- 2.93x
- ROE
- -38.1%
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 2 quarters up to Jun 2026.
Is 30S.F undervalued?
Graham number30S.F trades 7.0% above its Graham number.
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
SANIONA AB (PUBL) fundamental analysis
No fundamental analysis for SANIONA AB (PUBL) yet.
SANIONA AB (PUBL) stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About SANIONA AB (PUBL)
Saniona AB (publ), a clinical-stage biopharmaceutical company, focuses on discovering, developing, and delivering innovative treatments for neurological and psychiatric disorders in Ireland, the United States, Germany, Denmark, and the United Kingdom. It also develops medicines modulating ion channels. The company's product includes Tesofensine, a monoamine reuptake inhibitor that has completed Phase 3 clinical trial to treat people with obesity; and Tesomet, an oral investi…
Full company profileSANIONA AB (PUBL) financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 2 quarters up to Jun 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
SANIONA AB (PUBL) annual financial statements (SEK; K = thousand, M = million, B = billion, T = trillion)
| Item | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|
| Income Statement | ||||||
| Revenue | 10.5M | 15.3M | 16.8M | 335M | 434M | 18.5M |
| Gross Profit | 5.85M | 10.8M | 11.8M | 330M | 429M | 12.0M |
| Operating Income | -412M | -226M | -79.3M | 239M | 275M | -229M |
| EBITDA | - | -198M | -82.0M | 222M | 314M | -217M |
| Net Income | -411M | -212M | -95.8M | 189M | 285M | -209M |
| EPS | -5.57 | -2.87 | -1.26 | 1.68 | 2.06 | -1.51 |
| Balance Sheet | ||||||
| Total Assets | 440M | 154M | 64.1M | 340M | 680M | 601M |
| Total Liabilities | 158M | 101M | 86.1M | 108M | 44.6M | 52.8M |
| Shareholders' Equity | 282M | 52.7M | -21.9M | 232M | 635M | 548M |
| Cash & Short-term Investments | 357M | 112M | 31.0M | 303M | 581M | 486M |
| Cash Flow | ||||||
| Operating Cash Flow | -345M | -282M | -72.5M | 248M | 274M | -195M |
| Capital Expenditure | 1.48M | 985K | 129K | 124K | 73.6M | 10.6M |
| Free Cash Flow | -347M | -283M | -72.7M | 248M | 200M | -205M |
| Ratios | ||||||
| ROE | -145.7% | -401.4% | - | 81.4% | 44.8% | -38.1% |
| ROA | -93.3% | -137.7% | -149.4% | 55.5% | 41.9% | -34.8% |
| Net Profit Margin | -3,921.5% | -1,384.3% | -568.9% | 56.4% | 65.5% | -1,130.7% |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
SANIONA AB (PUBL) dividends
SANIONA AB (PUBL) has not paid dividends in the last 5 fiscal years.
Who owns SANIONA AB (PUBL)
- Insiders 7.64%
- Institutions 24.18%
- Public & others 68.18%
- Shares outstanding 138M
- Free float 121M
SANIONA AB (PUBL) company profile
- Company name
- SANIONA AB (PUBL)
- Ticker
- 30S.F
- ISIN
- SE0005794617
- Exchange
- Frankfurt Exchange
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 44
- Fiscal year end
- December
- Address
- Murervangen 42, Glostrup, Denmark, 2600
- Phone
- 45 70 70 52 25
- Website
- saniona.com
About SANIONA AB (PUBL)
Saniona AB (publ), a clinical-stage biopharmaceutical company, focuses on discovering, developing, and delivering innovative treatments for neurological and psychiatric disorders in Ireland, the United States, Germany, Denmark, and the United Kingdom. It also develops medicines modulating ion channels. The company's product includes Tesofensine, a monoamine reuptake inhibitor that has completed Phase 3 clinical trial to treat people with obesity; and Tesomet, an oral investigational therapy that has completed Phase 2 clinical trial for the treatment of hypothalamic obesity and Prader-Willi syndrome; ACP-711, a positive allosteric modulator of GABAA a3 containing receptors that has completed Phase 1 clinical trial for the treatment of essential tremor; SAN903, a novel medicine based on inhibition of the calcium-activated potassium ion channel, which has completed preclinical development for the treatment of inflammatory bowel disease; SAN2219, a subtype selective positive allosteric modulator of GABAA a2- a3- and a5 that is in preclinical stage for treatment of acute repetitive seizures; SAN2355 to treat resistant focal onset seizures; SAN2668, a therapy for severe pediatric epilepsies, including developmental epileptic encephalopathies; and SAN2465, a negative allosteric modulator to treat major depressive disorder. It has research and collaboration agreements with Boehringer Ingelheim International GmbH to research, develop, manufacture, and commercialize therapeutics; license agreement with Productos Medix, S.A. de C.V. develop and commercialize tesofensine and/or Tesomet; research services agreement and a collaboration agreement with Cephagenix ApS to identify and develop novel migraine treatments; and research collaboration with AstronauTx to research, develop, manufacture, and commercialize therapeutics for Alzheimer's disease. The company was founded in 2011 and is headquartered in Glostrup, Denmark.
SANIONA AB (PUBL) management
9- Mr. Thomas Feldthus M.Sc., MBACo-Founder & CEO · born 1960
- Mr. Jorgen Drejer Ph.D.Founder, Deputy CEO & Deputy Chairman of the Board · born 1955
- Dr. Pierandrea Muglia M.D.Chief Medical Officer · born 1966
- Mr. Janus Schreiber LarsenChief Operational Officer · born 1972
- Ms. Karin Sandager Nielsen Ph.D.Chief Scientific Officer · born 1970
- Mr. Alex RodriguezHead of Toxicology
- Martin Damm OllingHead of Clinical Development
- Stina Westergaard FrederiksenHead of Clinical Operations
- Søren EbdrupHead of CMC